Series date: 
07/01/2023 - 7:00am CDT to 06/30/2024 - 4:00pm CDT

Please check the individual session for location or broadcast availability.  



Series Director

Quillan Huang, MD

Target Audience and Needs

Medical oncologists, hematologists, geneticists, and other healthcare professionals who treat patients with cancer need to receive regular updates on recent advances in tumor sequencing, identification of actionable mutations, and targeted treatments of tumor pathways. The tumor board aims to bridge the current practice gap between the tumor sequencing information currently available to clinicians and the potential for on-label or off-label targeted therapies especially through clinical trial referrals. The goal of the tumor board is to advance the knowledge of learners regarding the application and interpretation of next-generation sequencing results ultimately to improve oncology patient care.

Educational Methods

Educational methods will include lectures, case presentations, literature review, and panel discussion.


At the conclusion of the sessions, the participants should be able to:

  • Interpret molecular pathology reports and identify recommended guideline-supported therapy.
  • Assess the literature for promising off-label therapies or clinical trial avenues.
  • Recognize the strengths and limitations of different facets of molecular testing in oncology (e.g., liquid vs. solid biopsies, RNA-based vs. DNA-based testing).


Participants may be asked to complete a session evaluation.

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Series Coordinator 
Juana Arismendez
Series location: 
Baylor College of Medicine
One Baylor Plaza
Houston, TX 77030
United States


Session Date
BRAF/MEK inhibitors in a MEK-mutated melanoma patient 08/25/2023 - 1:00pm to 2:00pm CDT
Colon cancer with high TMB and POLE mutation 10/20/2023 - 1:00pm to 2:00pm CDT
NRG1 Fusion Lung Adenocarcinoma 02/23/2024 - 1:00pm to 2:00pm CST
Molecular Tumor Board 04/12/2024 - 1:00pm to 2:00pm CDT